Heron Therapeutics Inc.
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It … Read more
Heron Therapeutics Inc. (0J4V) - Net Assets
Latest net assets as of December 2025: $14.33 Million USD
Based on the latest financial reports, Heron Therapeutics Inc. (0J4V) has net assets worth $14.33 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($670.88 Million) and total liabilities ($656.54 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $14.33 Million |
| % of Total Assets | 2.14% |
| Annual Growth Rate | -9.41% |
| 5-Year Change | -81.52% |
| 10-Year Change | N/A |
| Growth Volatility | 133.82 |
Heron Therapeutics Inc. - Net Assets Trend (2012–2025)
This chart illustrates how Heron Therapeutics Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Heron Therapeutics Inc. (2012–2025)
The table below shows the annual net assets of Heron Therapeutics Inc. from 2012 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $14.33 Million | +142.59% |
| 2024-12-31 | $-33.65 Million | +0.95% |
| 2023-12-31 | $-33.97 Million | -350.32% |
| 2022-12-31 | $13.57 Million | -82.50% |
| 2021-12-31 | $77.57 Million | -67.20% |
| 2020-12-31 | $236.49 Million | -41.44% |
| 2019-12-31 | $403.83 Million | +9.10% |
| 2018-12-31 | $370.16 Million | +182.27% |
| 2017-12-31 | $131.14 Million | +717.08% |
| 2016-12-31 | $-21.25 Million | -117.99% |
| 2015-12-31 | $118.11 Million | +87.29% |
| 2014-12-31 | $63.06 Million | -8.53% |
| 2013-12-31 | $68.94 Million | +33.05% |
| 2012-12-31 | $51.82 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Heron Therapeutics Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 175620200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.88 Million | 13.14% |
| Other Comprehensive Income | $4.00K | 0.03% |
| Other Components | $1.95 Billion | 13620.56% |
| Total Equity | $14.33 Million | 100.00% |
Heron Therapeutics Inc. Competitors by Market Cap
The table below lists competitors of Heron Therapeutics Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Motorpoint Group plc
PINK:MTPTF
|
$113.82 Million |
|
Maider Medical Industry Equipment Co Ltd
SHG:688310
|
$113.85 Million |
|
MacroGenics Inc
NASDAQ:MGNX
|
$113.87 Million |
|
OPORTUN FINL. DL-0001
F:4L0
|
$113.88 Million |
|
Senao Networks
TWO:3558
|
$113.80 Million |
|
Franklin Covey Company
NYSE:FC
|
$113.68 Million |
|
Beacon Minerals Limited
AU:BCN
|
$113.68 Million |
|
GOME Retail Holdings Limited
PINK:GMELF
|
$113.64 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Heron Therapeutics Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -33,651,000 to 14,333,000, a change of 47,984,000.
- Net loss of 20,195,000 reduced equity.
- Other comprehensive income decreased equity by 9,000.
- Other factors increased equity by 68,188,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-20.20 Million | -140.9% |
| Other Comprehensive Income | $-9.00K | -0.06% |
| Other Changes | $68.19 Million | +475.74% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Heron Therapeutics Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 9.90x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.20x to 9.90x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $4.24 | $0.85 | x |
| 2013-12-31 | $4.27 | $0.85 | x |
| 2014-12-31 | $2.37 | $0.85 | x |
| 2015-12-31 | $3.57 | $0.85 | x |
| 2016-12-31 | $-0.56 | $0.85 | x |
| 2017-12-31 | $2.43 | $0.85 | x |
| 2018-12-31 | $5.06 | $0.85 | x |
| 2019-12-31 | $4.94 | $0.85 | x |
| 2020-12-31 | $2.61 | $0.85 | x |
| 2021-12-31 | $0.79 | $0.85 | x |
| 2022-12-31 | $0.12 | $0.85 | x |
| 2023-12-31 | $-0.25 | $0.85 | x |
| 2024-12-31 | $-0.22 | $0.85 | x |
| 2025-12-31 | $0.09 | $0.85 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Heron Therapeutics Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -140.90%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -13.04%
- • Asset Turnover: 0.23x
- • Equity Multiplier: 46.81x
- Recent ROE (-140.90%) is above the historical average (-174.52%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -47.15% | 0.00% | 0.00x | 1.08x | $-29.61 Million |
| 2013 | -80.18% | 0.00% | 0.00x | 1.10x | $-62.18 Million |
| 2014 | -121.10% | 0.00% | 0.00x | 1.22x | $-82.67 Million |
| 2015 | -82.63% | 0.00% | 0.00x | 1.17x | $-109.40 Million |
| 2016 | 0.00% | -13537.37% | 0.02x | 0.00x | $-171.02 Million |
| 2017 | -150.59% | -641.87% | 0.13x | 1.79x | $-210.60 Million |
| 2018 | -48.31% | -230.84% | 0.17x | 1.25x | $-215.86 Million |
| 2019 | -50.70% | -140.27% | 0.28x | 1.27x | $-245.13 Million |
| 2020 | -96.10% | -256.41% | 0.25x | 1.50x | $-250.93 Million |
| 2021 | -284.50% | -255.58% | 0.28x | 3.94x | $-228.44 Million |
| 2022 | -1341.17% | -169.05% | 0.43x | 18.49x | $-183.38 Million |
| 2023 | 0.00% | -87.02% | 0.57x | 0.00x | $-107.16 Million |
| 2024 | 0.00% | -9.41% | 0.62x | 0.00x | $-10.21 Million |
| 2025 | -140.90% | -13.04% | 0.23x | 46.81x | $-21.63 Million |
Industry Comparison
This section compares Heron Therapeutics Inc.'s net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Heron Therapeutics Inc. (0J4V) | $14.33 Million | -47.15% | 45.81x | $113.82 Million |
| Nyfosa AB (0A0K) | $2.92 Billion | 39.50% | 2.88x | $973.31 Million |
| High Templar Tech Limited (0A2T) | $12.52 Billion | 4.70% | 0.13x | $255.82 Million |
| Strategy Inc (0A7O) | $51.04 Billion | -7.54% | 0.21x | $40.17 Billion |
| NACON SASU (0A9N) | $67.54 Million | 15.85% | 1.20x | $7.64 Million |
| Antin Infrastructure Partners (0AA5) | $23.79 Million | 108.98% | 1.09x | $573.10 Million |
| Truecaller AB Series B (0AA7) | $1.41 Billion | 18.30% | 0.20x | $281.60 Million |
| Brockhaus Technologies AG (0AAW) | $254.92 Million | -6.23% | 1.68x | $74.40 Million |
| Hyloris Pharmaceuticals S.A. (0AB6) | $48.06 Million | -24.09% | 0.32x | $71.96 Million |
| Kalray S.A. (0ABT) | $28.43 Million | -41.56% | 0.67x | $33.84 Million |
| Webuild S.p.A. (0BJP) | $1.43 Billion | 10.29% | 7.14x | $1.13 Billion |